Objective: Serum amyloid A (SAA) is an acute phase inflammatory marker that is closely associated with ischemic injuries. Its expression in neonatal hypoxic ischemic encephalopathy (HIE) has not been studied. To test the hypothesis that SAA is increased in neonatal HIE and its concentration correlates with the severity of encephalopathy.
Introduction
Asphyxia neonatorum before, during and after birth is one of the most important factors contributing to neonatal morbidity and mortality worldwide. Twenty five percent of neonates with hypoxic ischemic encephalopathy (HIE) develop severe and permanent neurological sequelae including mental retardation, cerebral palsy and epilepsy. 1 Hypoxia ischemia triggers a cascade of adverse events that leads to irreversible neuronal and white matter injury over a period of hours to days. Cellular loss occurs in the primary phase of energy failure. After subsequent reperfusion and oxygenation, brain metabolism may recover but then deteriorates in a secondary phase that emerges in the following 6 to 48 h. 2 During this second energy failure, lipids and proteins are oxidized, cytokines and excitatory proteins are overexpressed, apoptosis occurs and mechanisms for neuroprotection and repair are activated. Thus, neonatal outcomes are determined not only by the initial injury to the brain but also by the subsequent inflammatory mechanisms and the protective measures experienced during the secondary phase. 3 Despite the enthusiastic efforts to set up new therapeutic modalities for HIE and the increasing knowledge about the pathogenesis of asphyxia-related disorders, it is often difficult to predict which newborn will develop neurological problems. The currently known markers for perinatal asphyxia lack specificity, implicating the need for other predictors for adverse neurological outcomes in infants with of HIE. 4 Serum amyloid A (SAA) is an apolipoprotein that is found in the high-density lipoprotein fraction of serum and is involved in the chemotactic recruitment of inflammatory cells to the site of inflammation. 5 The response of SAA to stress, in general, and to tissue injury in particular has stimulated our interest to conduct this study in infants with asphyxia because of several reasons. First, SAA is an acute phase first class protein that increases in inflammation. 6, 7 The expression of SAA is largely triggered by increased circulatory concentrations of the proinflammatory cytokines: interleukins 1b and 6, and tumor necrosis factor-a, all of which are currently used as markers for HIE. 8 Second, although SAA is released in acute inflammation in general, it is considered a more specific marker for ischemia-related inflammation, 9,10 the condition that exactly pertains to HIE. For example, SAA has been shown to increase in patients with atherosclerosis and coronary artery disease. 9 Third, rather than just being a marker, SAA has been suggested to have a role in the pathogenesis of inflammation and its reduction can potentially be helpful in the treatment of ischemic disease. Patients with chronically increased SAA are considered at risk to develop vascular accidents. 11 Fourth, SAA correlates accurately not only with acute inflammation but also with intensity and degree of tissue damage and with cell necrosis. 6 Fifth, induction of SAA has been reported in brain cells of patients with other conditions such as Alzheimer's disease, macrophages and endothelial cells, all of which are involved in the pathogenesis of HIE.
In this prospective case-controlled study, we aim to assess the expression of serum SAA in neonates with evidence of perinatal compromise and examine its correlation with clinical grades of encephalopathy. To our knowledge, this is the first study to examine SAA in infants with HIE.
Methods

Patients
This prospective case-control study was conducted on 27 full-term or near-term neonates diagnosed with asphyxia and admitted to the neonatal intensive care unit (NICU) at Cairo University during the period of February 2008 to August 2009. Cases included in the study were full-term and near-term infants (gestational age 36 weeks) with perinatal compromise that was evidenced by at least two of the following; Apgar score p3 at 1 min or p6 at 5 min, umbilical cord arterial pH p7.2 with base deficit X10 mmol l À1 and the presence of postnatal clinical complications attributed to hypoxia ischemia, such as seizures, abnormality in the state of consciousness, hypotension requiring inotropic support, severe apnea and oliguria. 12 An age-matched control group (n ¼ 27) of apparently healthy newborns were recruited. Infants were excluded from the study if they met any of the following conditions: (a) conditions known to increase SAA such as sepsis or localized infection, (b) major congenital anomalies, (c) inborn errors of metabolism and (d) preterm births before 36 completed weeks. Blood cultures were obtained from all cases on admission to the NICU. As per routine care, serial samples were obtained from cases to measure qualitative C-reactive protein during NICU stay; it was considered positive when concentration was >6 mg 100 ml À1 . Full maternal and perinatal history was obtained for all cases and controls. Full neurological examination was assessed during the first 24 h of life including level of consciousness (alert, lethargy, or coma), muscle tone, tendon and complex reflexes, seizures and autonomic functions. A single experienced investigator (A Lotfy) conducted all examinations while being masked to results of SAA assays. Encephalopathy was graded as mild, moderate and severe using the Sarnat and Sarnat system. 13 This study was approved by the ethics committee at Cairo University Children's Hospital and was conducted in accordance with the University bylaws for human research. Parental consents were obtained for all subjects.
SAA assay
Assays for SAA were done in the first 24 h of age and repeated at the seventh postnatal day. For infants in the control group, (SAA-7) was obtained during their routine visit to the primary care pediatrician at day of life 7. Blood was drawn using standard venipuncture techniques. Samples were allowed to clot for 1 h at room temperature, centrifuged for 10 min and serum was extracted. Collected serum was stored at À20 1C. A quantitative measurement of SAA was performed using an ELISA applying a quantitative sandwich immunoassay. The provided microtiter plate had been pre-coated with a monoclonal antibody specific for SAA. Standards or samples were added to the appropriate microtiter plate wells and incubated. If present, SAA would bind and became immobilized by the antibody pre-coated on the wells. The microtiter plate wells were thoroughly washed to remove any unbound SAA and other sample components. In order to quantitate the amount of SAA present in the sample, a standardized preparation of horseradish peroxidase-conjugated polyclonal antibody specific for SAA was added to each well to 'sandwich' the SAA immobilized during the first incubation. The microtiter plate was allowed for a second incubation. The wells were thoroughly washed to remove all unbound horseradish peroxidase-conjugated antibodies and a TMB (3,3 0 5,5 0 -tetramethyl-benzidine) substrate solution was added to each well. The enzyme (horseradish peroxidase) and substrate solution was allowed to react over a short incubation period. Only those wells that contained SAA and enzyme-substrate reaction would exhibit a change in color. The enzyme-substrate reaction was terminated by the addition of sulfuric acid solution and the intensity of the color was measured.
Sample size calculation and statistical analysis On the basis of previously measured SAA concentrations in noninfected neonates (5.74±5.61 mg ml À1 ), 7 the sample size required to detect 70% increase in the concentration of SAA in HIE infants was 25 subjects in each group (power ¼ 80%, a ¼ 0.05). To compensate for any subject attrition due to mortality in HIE group or lost to follow-up in the control group, we increased the sample size to 27 subjects in each group. The statistical analysis was conducted using the commercial SPSS software version 13.0 (Chicago, IL, USA). Comparisons between groups were done using Fisher's exact test, t-test and Mann-Whitney test for categorical, continuous parametric and continuous non-parametric variables, respectively. Spearman's correlation test was used to examine the correlation SAA concentrations with pH and Apgar scores. Logistic regression was used to examine the association of SAA grades of HIE severity. Multiple regression analyses were used to eliminate the effect of maternal and neonatal confounding variables including maternal hypertension, diabetes, prolonged rupture of membranes and infant's sex. Data were expressed as mean ± s.d. Significance was considered when P<0.05.
Results
A total of 54 infants were studied, of them, 27 cases and 27 controls. The demographical and clinical characteristics of the study population are presented in Table 1. Table 2 describes the resuscitation in delivery room, the results of the analysis of the initial arterial blood gases and the severity of the developed encephalopathy of all cases. A total of eight (30%) cases died before hospital discharge, of them four died before 7 days and hence SAA at day 7 was not assessed in these infants. Blood cultures were negative in all enrolled subjects. C-reactive protein was positive after the third day of life in seven cases; none of them showed any clinical or hematological signs of sepsis.
At the time of hospital discharge, 11 infants had normal neurological examinations and 8 infants were abnormal. Neurological abnormalities included decreased muscle tone (n ¼ 4), increased tone (n ¼ 1) and abnormal reflexes (n ¼ 3). Mortality was associated with the more severe stages of HIE (P ¼ 0.05).
SAA at day 1 was significantly higher in cases when compared with controls (P<0.001); within cases, SAA at day 1 was higher in those who died compared with those who survived (P ¼ 0.002) (Figure 1) . Infants with pH<7, base deficit 16 and/or Apgar at 5 min p5 had higher SSA at day 1 when compared with the rest SAA at day 7 in was higher in cases as compared with controls (P<0.001), but within cases there was no difference between those who died and those who survived (P ¼ À0.2) (Figure 1 ). SSA at day 7 significantly correlated with grades of encephalopathy (P<0.001, r ¼ 0.66) (Figure 2 ) and negatively correlated with pH values (P<0.01, r ¼ À0.66). There were not enough samples to compare SAA-7 in cases with pH<7, base deficit X16 and/or Apgar p5 at 5 min with the rest of cases.
Using logistic regression analysis, SSA at day 1 did not associate with sex, mode of delivery, maternal hypertension and diabetes; it did not associate with the severity of base deficit measured in the initial blood gas (P ¼ 0.07). After controlling for the above-mentioned maternal and neonatal factors in a multiple regression analysis, mortality was associated with SSA at day 1 (P ¼ 0.02) but not with SSA at day 7 (P ¼ 0.14).
Using the ROC curve, SSA at day 1 could significantly predict mortality of the studied cases with a sensitivity of 75% and a specificity of 100% (cutoff point ¼ 97.5 mg ml À1 , area under the curve ¼ 0.76, and P ¼ 0.034) (Figure 3) .
Discussion
This is the first study to demonstrate increased expression of SAA in infants with perinatal compromise and significant association of SAA with grades of encephalopathy and mortality. SAA was not previously monitored as a marker for encephalopathy, yet we had enough leads to investigate such a relationship. In response to inflammation, trauma and infection, the body has an innate defense mechanism which involves the expression of different acute phase reactant mediators including SAA.
14 Such a response is universal in humans and animals. 6, [14] [15] [16] The expression of these proinflammatory markers tends to fade after the conclusion of the acute phase of inflammation. Therefore, the expression of many of these cytokines early in the disease does not necessarily indicate cell damage and does not ultimately correlate with long-term consequences following the initial insult. One of the specific features that drew our attention to SAA is its expression in patients suffering from ischemic insults in atherosclerosis and coronary artery diseases. 9 Indeed, higher concentrations of SAA in a non-symptomatic individual are indicative for impending vascular accidents.
11 SAA is also a sensitive marker for the intensity of injury in other acute and chronic illnesses that involve cell necrosis such as: traumatic events, arthritis, viral infections and malignant diseases. 6 Although hypoxia ischemia of the newborn is known to trigger an acute phase inflammatory response, it may also lead to later development of neuronal damage, tissue necrosis and devastating clinical outcomes. 15 It is plausible to expect SAA expression to reflect both the acute phase and the later-onset cell death. Previous studies demonstrated that surgical stress, length of operation and possible risks 72 h after operation were best predicted by the C-reactive protein and SAA; during which time other markers of inflammation, such as IL-6 and leukocytic count, were normal. 17 Following hypoxia ischemia, reperfusion ensues with massive production of free radicals and other oxidative molecules that exceed the capacity of the body's antioxidant defenses, 18 this oxidative stress triggers a cascade of reactions leading to cell necrosis and apoptosis. The expression of SAA herein is not only a reactant to the initial inflammation, but it is also a reflection of the degree of cell death.
SAA at day 1 and at day 7 correlated negatively with pH values. The more severe the diagnosis of acidosis, the higher was the expression of SAA. Of note, the average pH in infants of this study was 7.09 indicating that the degree of acidosis was generally milder than the ordinarily used criteria for acidosis (pH <7) in previous studies.
Although SAA was not associated with maternal hypertension, diabetes, mode of delivery or the sex of the newborn, these findings should be cautiously interpreted because the study's sample size was not powered to examine these associations. However, previous animal 19 and human 20 studies have not linked SAA with these maternal conditions either; this further implicates that SAA does not increase in stressful conditions that do not commonly lead to tissue damage or necrosis. We speculate that increased SAA in asphyxia is a true marker for the amount of tissue damage and unlike other markers, 21 it is not just a reflection of the acute inflammatory response that follows hypoxia ischemia.
The majority of cases (70%) were males; the clear predominance of perinatal compromise in males is not an accidental finding and this relationship has been the focus of several studies. [22] [23] [24] Hypotheses regarding the male predominance include dysfunction of the placenta or increased metabolic demands in male fetuses. 25, 26 Although some studies on adults correlated the increased expression of inflammatory markers, including SAA, with adiposity and stated that the association was considerably stronger in adult females, 27 this observation is not necessarily applicable to asphyxiated infants. Therefore, we utilized a regression model to control for influence of gender on SAA.
SAA was capable of predicting mortality in cases. Previous studies suggested several sensitive proinflammatory markers for predicting outcomes of encephalopathy in neonates; however, they lacked specificity. Opposingly, SAA in our study proved to be very reliable in predicting severity of injury that led to mortality. We believe this SAA feature is a reflection of its nature as a marker for ischemia and cell necrosis. This observation is also consistent with findings wherein SAA remained significantly increased in asphyxiated infants even 1 week after the hypoxic insult. The marked variation between the response of SAA and other inflammatory markers in response to different stimuli such as surgical trauma and immunological tissue injury suggests the existence of independent pathways for SAA regulation. 28 For example, studies performed on cases of cardiac infarction secondary to coronary artery syndrome showed a better capability of SAA to predict clinical outcomes as opposed to the C-reactive protein. 10 This study adds the following novel information: (a) SAA is upregulated in newborn with perinatal compromise and asphyxia, (b) the concentrations of SAA correlate with the severity of encephalopathy, (c) the high expression of SAA continues for the 1-week duration of the study and (d) higher SAA expression is a marker for mortality in these infants. We suggest that future studies examine the association between SAA expression and abnormal long-term neurological outcome in post-asphyxial survivors, and to compare it with the expression of other markers for asphyxia. It is also important to compare SAA expression in infants with HIE, with infants with other inflammatory conditions to examine the specificity of this marker.
